As a notable example, Brolucizumab (Beovu) is the first FDA approved rabbit-derived scFv used as vascular endothelial growth factor (VEGF) inhibitor for the treatment of exudative (wet) age-related macular degeneration (AMD), diabetic macular oedema and macular oedema secondary to retinal vein occlusion, which could better overcome the possible side effects (discomfort and increased tears in the affected eyes, itchy or watery eyes, dry eyes, swelling of the eyelids, etc.)of murine-derived IgG-Fab fragment (Lucentis) [17]. The gene discussed is VEGFA; the disease is Keratoconjunctivitis sicca.